Skin Cancer | Topics

 
FDA Expands Indication for Pembrolizumab in Locally Advanced CSCC
July 06, 2021

Pembrolizumab has been granted an expanded indication by the FDA for locally advanced cutaneous squamous cell carcinoma.

Pembrolizumab Induces Robust, Durable Antitumor Activity in Advanced CSCC
April 11, 2021

These data establish pembrolizumab as a promising treatment option for those with locally advanced and recurrent/metastatic cutaneous squamous cell carcinoma, according to Brett G.M. Hughes, MD.

First-Line Nivolumab Plus Ipilimumab Improves OS Versus Chemo in Patients with Metastatic Uveal Melanoma
February 11, 2021

First-line treatment with nivolumab plus ipilimumab showed a moderate improvement in overall survival and a manageable safety profile in patients with metastatic uveal melanoma.